Zobrazeno 1 - 10
of 654
pro vyhledávání: '"Ian Chau"'
Autor:
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor
Externí odkaz:
https://doaj.org/article/df5ecc4526e845d49481ee6aa799d831
Autor:
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/59c4231e83f941f6a4719927e06f1ef1
Autor:
Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O’Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of
Externí odkaz:
https://doaj.org/article/1fe44534f0e94c6a89809b887b29866b
Autor:
Vicky Coyle, Caroline Forde, Richard Adams, Ashley Agus, Rosemary Barnes, Ian Chau, Mike Clarke, Annmarie Doran, Margaret Grayson, Danny McAuley, Cliona McDowell, Glenn Phair, Ruth Plummer, Dawn Storey, Anne Thomas, Richard Wilson, Ronan McMullan
Publikováno v:
Health Technology Assessment, Vol 28, Iss 14 (2024)
Background Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy. Objectives To establish th
Externí odkaz:
https://doaj.org/article/d65b0b41216d4cb6b4b56e317dcd6595
Autor:
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThis study aimed to identify microRNAs (miRs) as circulating biomarkers of resistance to first-line trastuzumab-based therapy in advanced HER2-positive oesophago-gastric cancer patients.MethodsA high-throughput 1015 Exiqon miRCURY LNA™ mi
Externí odkaz:
https://doaj.org/article/ce00e101c55741ff998c109728418068
Autor:
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
Externí odkaz:
https://doaj.org/article/8c4c528d564e402aa51ff80d19849ea5
Autor:
Dima El-Sharkawi, Amit Sud, Catherine Prodger, Jahanzaib Khwaja, Rohan Shotton, Brian Hanley, Victoria Peacock, Ying Ying Peng, Anita Arasaretnam, Sarkhara Sharma, Frances Aldridge, Bhupinder Sharma, Andrew Wotherspoon, Betty Cheung, Corinne De Lord, Rosalynd Johnston, Shireen Kassam, Ruth Pettengel, Kim Linton, Paul Greaves, Lucy Cook, Kikkeri N. Naresh, Kate Cwynarski, Toby A. Eyre, Ian Chau, David Cunningham, Sunil Iyengar
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-5 (2023)
Externí odkaz:
https://doaj.org/article/f34c82b257694a09bb76d27d1f3ce733
Autor:
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana, Maria Aresu, Clare Peckitt, Oleg Zhitkov, Retchel Lazaro-Alcausi, Victoria Borja, Rachel Powell, David Lowery, Michael Hubank, Thereasa Rich, Gayathri Anandappa, Ian Chau, Naureen Starling, David Cunningham
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to gu
Externí odkaz:
https://doaj.org/article/fd82327f73c3444fa40eeb618feddeee
Autor:
Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102015- (2023)
Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no stan
Externí odkaz:
https://doaj.org/article/17e61c62deeb4eef9d3d7c4b9df3c376
Autor:
Fiona Turkes, Annette Bryant, Ruwaida Begum, Michael Davidson, Eleftheria Kalaitzaki, Maria Aresu, Retchel Lazaro-Alcausi, Jane Bryant, Isma Rana, Sue Chua, Lauren Aronson, Sanna Hulkki-Wilson, Charlotte Fribbens, David Watkins, Sheela Rao, Naureen Starling, David Cunningham, Irene Y. Chong, Ian Chau
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2174-2184 (2022)
Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of
Externí odkaz:
https://doaj.org/article/5d5338a80b2f46c49f2a37fe4ad17d3e